JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

(2015) R. S. Komrokji et al.   BLOOD

In vitro transfusion of red blood cells results in decreased cytokine production by human T cells

(2014) Kristin Long et al.   Journal of Trauma and Acute Care Surgery

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

(2013) A. Tefferi et al.   BLOOD

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

(2013) G. Barosi et al.   BLOOD

An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor

(2013) Nicholas G. Wysham et al.   CHEST

The Multifaceted Role of Th17 Lymphocytes and Their Associated Cytokines in Cancer

(2013) Darya Alizadeh et al.   Clinical & Developmental Immunology

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis

(2013) G Caocci et al.   LEUKEMIA

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

(2013) T Zhou et al.   LEUKEMIA

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib

(2013) M Massa et al.   LEUKEMIA

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

(2013) A Pardanani et al.   LEUKEMIA

Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib

(2013) Rowan Wathes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib

(2013) Roger A. Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis

(2012) Rakhee Vaidya et al.   AMERICAN JOURNAL OF HEMATOLOGY

Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

(2012) H. C. Hasselbalch   BLOOD

Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ T regulatory cell subpopulations

(2012) C. Scotta et al.   HAEMATOLOGICA

Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

(2012) Hans Carl Hasselbalch   LEUKEMIA RESEARCH

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

TNF  facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

(2011) A. G. Fleischman et al.   BLOOD

Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN- 

(2011) C. H. Riley et al.   BLOOD

Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection

(2011) J. Cowan et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

(2011) Masahiko Mihara et al.   CLINICAL SCIENCE

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy

(2010) Robert Zeiser et al.   CELL CYCLE

Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive Mice

(2010) Madhav D. Sharma et al.   IMMUNITY

Human Th17 Cells Comprise Heterogeneous Subsets Including IFN- -Producing Cells with Distinct Properties from the Th1 Lineage

(2010) K. Boniface et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Mechanisms of IL-2-Dependent Maintenance of Functional Regulatory T Cells

(2010) L. Barron et al.   JOURNAL OF IMMUNOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-17-producing CD4+T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome

(2009) Shahram Y. Kordasti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL